Cargando…

Outcome-based reimbursement in Central-Eastern Europe and Middle-East

Outcome-based reimbursement models can effectively reduce the financial risk to health care payers in cases when there is important uncertainty or heterogeneity regarding the clinical value of health technologies. Still, health care payers in lower income countries rely mainly on financial based agr...

Descripción completa

Detalles Bibliográficos
Autores principales: Ádám, Ildikó, Callenbach, Marcelien, Németh, Bertalan, Vreman, Rick A., Tollin, Cecilia, Pontén, Johan, Dawoud, Dalia, Elvidge, Jamie, Crabb, Nick, van Waalwijk van Doorn-Khosrovani, Sahar Barjesteh, Pisters-van Roy, Anke, Vincziczki, Áron, Almomani, Emad, Vajagic, Maja, Oner, Z. Gulsen, Matni, Mirna, Fürst, Jurij, Kahveci, Rabia, Goettsch, Wim G., Kaló, Zoltán
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9539523/
https://www.ncbi.nlm.nih.gov/pubmed/36213666
http://dx.doi.org/10.3389/fmed.2022.940886
_version_ 1784803506642747392
author Ádám, Ildikó
Callenbach, Marcelien
Németh, Bertalan
Vreman, Rick A.
Tollin, Cecilia
Pontén, Johan
Dawoud, Dalia
Elvidge, Jamie
Crabb, Nick
van Waalwijk van Doorn-Khosrovani, Sahar Barjesteh
Pisters-van Roy, Anke
Vincziczki, Áron
Almomani, Emad
Vajagic, Maja
Oner, Z. Gulsen
Matni, Mirna
Fürst, Jurij
Kahveci, Rabia
Goettsch, Wim G.
Kaló, Zoltán
author_facet Ádám, Ildikó
Callenbach, Marcelien
Németh, Bertalan
Vreman, Rick A.
Tollin, Cecilia
Pontén, Johan
Dawoud, Dalia
Elvidge, Jamie
Crabb, Nick
van Waalwijk van Doorn-Khosrovani, Sahar Barjesteh
Pisters-van Roy, Anke
Vincziczki, Áron
Almomani, Emad
Vajagic, Maja
Oner, Z. Gulsen
Matni, Mirna
Fürst, Jurij
Kahveci, Rabia
Goettsch, Wim G.
Kaló, Zoltán
author_sort Ádám, Ildikó
collection PubMed
description Outcome-based reimbursement models can effectively reduce the financial risk to health care payers in cases when there is important uncertainty or heterogeneity regarding the clinical value of health technologies. Still, health care payers in lower income countries rely mainly on financial based agreements to manage uncertainties associated with new therapies. We performed a survey, an exploratory literature review and an iterative brainstorming in parallel about potential barriers and solutions to outcome-based agreements in Central and Eastern Europe (CEE) and in the Middle East (ME). A draft list of recommendations deriving from these steps was validated in a follow-up workshop with payer experts from these regions. 20 different barriers were identified in five groups, including transaction costs and administrative burden, measurement issues, information technology and data infrastructure, governance, and perverse policy outcomes. Though implementing outcome-based reimbursement models is challenging, especially in lower income countries, those challenges can be mitigated by conducting pilot agreements and preparing for predictable barriers. Our guidance paper provides an initial step in this process. The generalizability of our recommendations can be improved by monitoring experiences from pilot reimbursement models in CEE and ME countries and continuing the multistakeholder dialogue at national levels.
format Online
Article
Text
id pubmed-9539523
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-95395232022-10-08 Outcome-based reimbursement in Central-Eastern Europe and Middle-East Ádám, Ildikó Callenbach, Marcelien Németh, Bertalan Vreman, Rick A. Tollin, Cecilia Pontén, Johan Dawoud, Dalia Elvidge, Jamie Crabb, Nick van Waalwijk van Doorn-Khosrovani, Sahar Barjesteh Pisters-van Roy, Anke Vincziczki, Áron Almomani, Emad Vajagic, Maja Oner, Z. Gulsen Matni, Mirna Fürst, Jurij Kahveci, Rabia Goettsch, Wim G. Kaló, Zoltán Front Med (Lausanne) Medicine Outcome-based reimbursement models can effectively reduce the financial risk to health care payers in cases when there is important uncertainty or heterogeneity regarding the clinical value of health technologies. Still, health care payers in lower income countries rely mainly on financial based agreements to manage uncertainties associated with new therapies. We performed a survey, an exploratory literature review and an iterative brainstorming in parallel about potential barriers and solutions to outcome-based agreements in Central and Eastern Europe (CEE) and in the Middle East (ME). A draft list of recommendations deriving from these steps was validated in a follow-up workshop with payer experts from these regions. 20 different barriers were identified in five groups, including transaction costs and administrative burden, measurement issues, information technology and data infrastructure, governance, and perverse policy outcomes. Though implementing outcome-based reimbursement models is challenging, especially in lower income countries, those challenges can be mitigated by conducting pilot agreements and preparing for predictable barriers. Our guidance paper provides an initial step in this process. The generalizability of our recommendations can be improved by monitoring experiences from pilot reimbursement models in CEE and ME countries and continuing the multistakeholder dialogue at national levels. Frontiers Media S.A. 2022-09-23 /pmc/articles/PMC9539523/ /pubmed/36213666 http://dx.doi.org/10.3389/fmed.2022.940886 Text en Copyright © 2022 Ádám, Callenbach, Németh, Vreman, Tollin, Pontén, Dawoud, Elvidge, Crabb, van Waalwijk van Doorn-Khosrovani, Pisters-van Roy, Vincziczki, Almomani, Vajagic, Oner, Matni, Fürst, Kahveci, Goettsch and Kaló. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Medicine
Ádám, Ildikó
Callenbach, Marcelien
Németh, Bertalan
Vreman, Rick A.
Tollin, Cecilia
Pontén, Johan
Dawoud, Dalia
Elvidge, Jamie
Crabb, Nick
van Waalwijk van Doorn-Khosrovani, Sahar Barjesteh
Pisters-van Roy, Anke
Vincziczki, Áron
Almomani, Emad
Vajagic, Maja
Oner, Z. Gulsen
Matni, Mirna
Fürst, Jurij
Kahveci, Rabia
Goettsch, Wim G.
Kaló, Zoltán
Outcome-based reimbursement in Central-Eastern Europe and Middle-East
title Outcome-based reimbursement in Central-Eastern Europe and Middle-East
title_full Outcome-based reimbursement in Central-Eastern Europe and Middle-East
title_fullStr Outcome-based reimbursement in Central-Eastern Europe and Middle-East
title_full_unstemmed Outcome-based reimbursement in Central-Eastern Europe and Middle-East
title_short Outcome-based reimbursement in Central-Eastern Europe and Middle-East
title_sort outcome-based reimbursement in central-eastern europe and middle-east
topic Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9539523/
https://www.ncbi.nlm.nih.gov/pubmed/36213666
http://dx.doi.org/10.3389/fmed.2022.940886
work_keys_str_mv AT adamildiko outcomebasedreimbursementincentraleasterneuropeandmiddleeast
AT callenbachmarcelien outcomebasedreimbursementincentraleasterneuropeandmiddleeast
AT nemethbertalan outcomebasedreimbursementincentraleasterneuropeandmiddleeast
AT vremanricka outcomebasedreimbursementincentraleasterneuropeandmiddleeast
AT tollincecilia outcomebasedreimbursementincentraleasterneuropeandmiddleeast
AT pontenjohan outcomebasedreimbursementincentraleasterneuropeandmiddleeast
AT dawouddalia outcomebasedreimbursementincentraleasterneuropeandmiddleeast
AT elvidgejamie outcomebasedreimbursementincentraleasterneuropeandmiddleeast
AT crabbnick outcomebasedreimbursementincentraleasterneuropeandmiddleeast
AT vanwaalwijkvandoornkhosrovanisaharbarjesteh outcomebasedreimbursementincentraleasterneuropeandmiddleeast
AT pistersvanroyanke outcomebasedreimbursementincentraleasterneuropeandmiddleeast
AT vincziczkiaron outcomebasedreimbursementincentraleasterneuropeandmiddleeast
AT almomaniemad outcomebasedreimbursementincentraleasterneuropeandmiddleeast
AT vajagicmaja outcomebasedreimbursementincentraleasterneuropeandmiddleeast
AT onerzgulsen outcomebasedreimbursementincentraleasterneuropeandmiddleeast
AT matnimirna outcomebasedreimbursementincentraleasterneuropeandmiddleeast
AT furstjurij outcomebasedreimbursementincentraleasterneuropeandmiddleeast
AT kahvecirabia outcomebasedreimbursementincentraleasterneuropeandmiddleeast
AT goettschwimg outcomebasedreimbursementincentraleasterneuropeandmiddleeast
AT kalozoltan outcomebasedreimbursementincentraleasterneuropeandmiddleeast